New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
06:10 EDTAKRXAkorn announces approval and launch of generic Prometrium
Akorn announced that its manufacturing and development partner, Sofgen Pharmaceuticals has received approval of its abbreviated new drug application, or ANDA, for Progesterone capsules, 100mg and 200mg. The approved ANDA is for the generic of Abbott Laboratories' Prometrium capsules indicated for the treatment of endometrial hyperplasia and secondary amenorrhea. Akorn has exclusive marketing rights to Sofgen's product in the U.S. and the Company has begun distribution. According to IMS Health, Progesterone capsules, 100mg and 200mg, had combined sales of approximately $170M in the U.S. based on annualizing the three months ended August 31. IMS Health sales figures exclude certain customary discounts and incentives.
News For AKRX From The Last 14 Days
Check below for free stories on AKRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
14:18 EDTAKRXAkorn competition settlement over VersaPharm deal approved by FTC
Subscribe for More Information
September 15, 2014
07:10 EDTAKRXAkorn potential KUDCo deal makes strategic sense, says Piper Jaffray
Subscribe for More Information
September 12, 2014
09:00 EDTAKRXNeedham skeptical of potential Akorn deal for Kremers
Subscribe for More Information
September 11, 2014
12:56 EDTAKRXAkorn exploring 'inversion' deal for Belgian drugmaker unit, Reuters says
Subscribe for More Information
12:55 EDTAKRXAkorn pursuing potential inversion deal for UCB unit, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use